This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
by Zacks Equity Research
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Supernus Pharmaceuticals (SUPN) stock based on the movements in the options market lately
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What Makes Supernus (SUPN) a New Buy Stock
by Zacks Equity Research
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround
by Zacks Equity Research
Supernus (SUPN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 1.69% and 1.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?